Nucleotide Analogue-Related Proximal Renal Tubular Dysfunction during Long-Term Treatment of Chronic Hepatitis B: A Cross-Sectional Study
Table 2
Blood and urine chemistries of 92 patients treated with nucleotide analogues according to the severity of proximal renal tubular dysfunction (RTD).
Normal ()
Subclinical proximal RTD ()
Overt proximal RTD ()
AST (IU/L)
38.9 ± 21.7
34.4 ± 9.3
29.1 ± 7.6
0.30
ALT (IU/L)
53.8 ± 35.8
50.7 ± 26.9
35.7 ± 7.7
0.31
ALP (IU/L)
74.7 ± 18.8
89.3 ± 28.4
107.9 ± 60.3
0.036
Creatinine (mg/dL)
0.92 ± 0.2
1.05 ± 0.2
1.19 ± 0.2
0.002
GFR by CKD-EPI (mL/min)
86.7 ± 16.6
74.5 ± 16.0
59.9 ± 13.6
<0.001
Proteinuria, (%)
9 (13.2)
10 (66.7)
9 (100)
<0.001
Phosphaturia, (%)
9 (13.2)
13 (86.7)
9 (100)
<0.001
Uricosuria, (%)
0
5 (33.3)
9 (100)
<0.001
Glycosuria with normoglycemia, (%)
2 (2.9)
2 (13.3)
4 (44.4)
<0.001
Renal potassium loss, (%)
0
0
0
Normal gap acidosis, (%)
0
0
1 (11.1)
0.009
Median 24-hour urine protein (mg)
86 (0–425)
158 (55–437)
408 (190–939)
<0.001
Median UPCR (mg/mg)
0.10 (0–0.49)
0.18 (0.08–0.42)
0.54 (0.29–1.14)
<0.001
TmPO4/GFR (mg/dL)
2.9 0.5
2.3 0.3
1.7 0.7
<0.001
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GFR, glomerular filtration rate; UPCR, urine protein to creatinine ratio; TmPO4/GFR, tubular maximal reabsorption rate of phosphate to GFR. Data are expressed as mean SD unless otherwise indicated.
